Traders should prepare for potential volatility following the March 27 earnings release, particularly focusing on revenue trends, cash runway, and commercial progress of Symvess. Monitor management's commentary on regulatory timelines for additional ATEV indications.
Price Chart
Executive Summary
Humacyte announced it will release its Q4 and full-year 2025 financial results on March 27, 2026, followed by a management webcast and conference call. The press release contains no actual financial data, only logistical details about the upcoming earnings announcement.
Key Facts
- Humacyte will release 2025 fourth quarter and full-year financial results on March 27, 2026.
- Management will host a conference call and webcast at 8:00 a.m. ET to discuss results and provide a corporate update.
- No financial figures or operational updates were disclosed in this announcement.
- The company continues to advance its ATEV product pipeline, with Symvess already FDA-approved for vascular trauma.
Financial Impact
No financial data disclosed — impact depends on upcoming earnings release
Risk Factors
- Limited financial transparency ahead of earnings release increases uncertainty.
- Biotech commercialization risks remain high despite FDA approval in one indication.
- Low market cap ($164M) implies high sensitivity to earnings miss or guidance concerns.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260305 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $0.4400 | awaiting T+60 | — | $0.4010 (−8.86%) |
Aug 19, 2026 9w ago | Press Release | $0.7349 | awaiting T+60 | — | $0.4010 (−45.43%) |
Aug 12, 2026 10w ago | 8-K | $0.6650 | awaiting T+60 | — | $0.4010 (−39.70%) |
Aug 12, 2026 10w ago | Press Release | $0.6650 | awaiting T+60 | — | $0.4010 (−39.70%) |
Aug 7, 2026 11w ago | Press Release | $0.7180 | awaiting T+60 | — | $0.4010 (−44.15%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.06 $0.5790 | ▼ −45.12% | ▼ −47.90% | $0.4010 (−61.99%) |
Jun 11, 2026 19w ago | 8-K | $1.06 $0.5790 | ▲ +45.12% | ▲ +47.90% | $0.4010 (+61.99%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4010 (+62.87%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4010 (+62.87%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▼ −44.92% | ▼ −48.74% | $0.4010 (−62.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers